Pharmaceutical Control of Blood Diseases Market Analysis & Forecasts Report 2008

Table of Contents

Chapter 1: Executive Summary

Chapter 2: Blood Diseases and their Treatments

• 2.1 Functions of Blood
  • 2.1.1 Haemopoiesis
  • 2.1.2 Haemostasis
• 2.2 Anaemia
  • 2.2.1 Iron Deficiency
  • 2.2.2 Anaemia of Chronic Disease
  • 2.2.3 Megaloblastic Anaemia
  • 2.2.4 Pernicious Anaemia
  • 2.2.5 Aplastic Anaemia
  • 2.2.6 Haemolytic Anaemia
    • 2.2.6.1 Inherited Haemolytic Anaemia: Hereditary Spherocytosis, Hereditary Elliptocytosis, Thalassaemia, Sickle Cell Disease and Glucose-6-phosphate Deficiency
    • 2.2.6.2 Acquired Haemolytic Anaemia: Autoimmune Haemolytic Anaemia and Non-immune Haemolytic Anaemia
  • 2.2.7 Anaemia and Aging
• 2.3 Myeloproliferative and Myelodysplastic Disorders
  • 2.3.1 Polycythaemia: Polycythaemia Vera and Secondary Polycythaemia
  • 2.3.2 Primary Thrombocythaemia
  • 2.3.3 Primary Myelofibrosis (Myelosclerosis)
• 2.4 Bleeding Disorders
  • 2.4.1 Autoimmune Thrombocytopenic Purpura
  • 2.4.2 Inherited Coagulation Disorders
    • 2.4.2.1 Haemophilia A
    • 2.4.2.2 Haemophilia B
    • 2.4.2.3 Von Willebrand' s Disease
  • 2.4.3 Acquired Coagulation Disorders
    • 2.4.3.1 Disseminated Intravascular Coagulation
• 2.5 White Blood Cell Disorders
  • 2.5.1 Neutropenia
• 2.6 Thrombosis
  • 2.6.1 Arterial Thrombosis
  • 2.6.2 Venous Thrombosis

Chapter 3: Blood Diseases Treatments

• 3.1 Antithrombotic Treatments
  • 3.1.1 Platelet Aggregation Inhibitors
  • 3.1.2 Anticoagulants Injectable
  • 3.1.3 Anticoagulants Non-injectable
  • 3.1.4 Fibrinolytics
  • 3.1.5 Direct Thrombin Inhibitors
  • 3.1.6 Antithrombin III and Other Protease Inhibitors
  • 3.1.7 Other Antithrombotic Treatments
• 3.2 Anti-anaemic Treatments
  • 3.2.1 Erythropoietin Products
  • 3.2.2 Iron Replacement Therapy
  • 3.2.3 Other Anti-anaemic Treatments
• 3.3 Clotting Factors
• 3.4 Other Treatments

Chapter 4: Blood Diseases Treatments World Market

• 4.1 Market Analysis
• 4.2 Market Shares
• 4.3 Top Ten Drugs
• 4.4 Percentage Change 2006-2013

Chapter 5: Antithrombotics Market

• 5.1 Market Analysis
• 5.2 The Platelet Aggregation Inhibitors Dominate the Antithrombotics Market
• 5.3 Drugs Generating below $300m dominate the Antithrombotics Market
• 5.4 Platelet Aggregation Inhibitors Market
• 5.5 Plavix Dominates the Platelet Aggregation Inhibitors Market
• 5.6 Plavix
  • 5.6.1 Threat to Plavix' s Sales in 2006
  • 5.6.2 Plavix' s Competitors
  • 5.6.3 Plavix' s Loss of Patent Protection
• 5.7 Clopidogrel Aptx' s Withdrawal
• 5.8 Pletaal
  • 5.8.1 Pletaal' s Indications
  • 5.8.2 Potential Market Expansion for Pletaal
• 5.9 Integrilin
  • 5.9.1 The Leading Glycoprotein IIb/IIIa Receptor Inhibitor
  • 5.9.2 Integrilin' s Competitors
  • 5.9.3 Potential Market Expansion for Integrilin
• 5.10 Injectable Anticoagulants Market
• 5.11 Lovenox Dominates the Injectable Anticoagulants Market
• 5.12 Lovenox
  • 5.12.1 A Leading Low Molecular Weight Heparin
  • 5.12.2 Lovenox' s Loss of Patent Protection in 2012
  • 5.12.3 Potential Market Expansion for Lovenox
  • 5.12.4 Lovenox' s Competitors
• 5.13 Fraxiparine
• 5.14 Fragmin
• 5.15 Other Anti-thrombotics

Chapter 6: Anti-anaemics World Market

• 6.1 Market Analysis
• 6.2 Erythropoietin Products Dominate the Anti-anaemics Market
• 6.3 Aranesp Dominates the Anti-anaemics Market
• 6.4 Erythropoietin Products
• 6.5 Aranesp Dominates the Erythropoietin Products Market
• 6.6 Aranesp
  • 6.6.1 Fears over Erythropoietin Products Overuse
  • 6.6.2 Scope for Expansion of Aranesp' s Indications
  • 6.6.3 Aranesp' s Edge over Competitors
  • 6.6.4 Other Competitiors of Aranesp
  • 6.6.5 Entry of Erythropoietin Biosimilars in Europe
• 6.7 Erypo
  • 6.7.1 Generic versions of Erypo
• 6.8 Epogen
• 6.9 NeoRecormon
• 6.10 Espo
• 6.11 Iron Replacement Therapy
• 6.12 Drugs with Revenues less than $300m Dominate the Iron Replacement Therapy Market
• 6.13 Venofer
• 6.14 Other Anti-Anaemics

Chapter 7: Clotting Factors Market

• 7.1 Market Analysis
• 7.2 Novoseven' s Change in Market Share
• 7.3 NovoSeven

Chapter 8: Forces Affecting the Blood Diseases Treatments Market

• 8.1 SWOT Analysis of the Blood Diseases Treatments Market
• 8.2 Market Drivers
• 8.3 Market Restraints
• 8.4 Plavix and Parallel Trade
• 8.5 Strong developmental Pipeline for Drugs on Parr with Lovenox
• 8.6 Ongoing Fears Over the use of Erythropoietin Products in Cancer Patients
• 8.7 FDA Approves New Haemophilia Treatment

Chapter 9: Geographical Breakdown of the Blood Diseases Treatments Market

• 9.1 The US Holds over 50% Market Share of the Blood Diseases Treatments Market
• 9.2 Increasing Market Share of Developing Countries at the Cost of Developed Countries

Chapter 10: Pipeline Products

• 10.1 Anti-thrombotics in the Pipeline
• 10.2 Anti-Anaemics in the Pipeline
• 10.3 Clotting Factors in the Pipeline
• 10.4 Other Blood Diseases Treatments in the Pipeline

Chapter 11: Conclusion

• 11.1 Blood Diseases and Treatments
• 11.2 Blood Diseases Treatments World Market
• 11.3 Blood Diseases Treatments Market Segments
• 11.4 Issues and Opportunities
• 11.5 Products in Development
• 11.6 Geographical Breakdown of the Market
• 11.7 Afterword

List of Tables

• Table 4.1: Forecasts for Blood Diseases Treatments, 2006-2013
• Table 4.2: Forecasts for Blood Diseases Treatments 2018 and 2023
• Table 4.3: Top Ten Products in the Blood Diseases Treatment World Market 2006
• Table 5.1: Antithrombotics Market Forecast, 2006-2013
• Table 5.2: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
• Table 5.3: Forecasts for Platelet Aggregation Inhibitors, 2018 and 2023
• Table 5.4: Injectable Anticoagulants Market Forecast, 2006-2013
• Table 5.5: Injectable Anticoagulants Market Forecast, 2018 and 2023
• Table 6.1: Anti-anaemics Market Forecast, 2006-2013
• Table 6.2: Anti-anaemics Market Forecast, 2018 and 2023
• Table 6.3: Forecasts for Erythropoietin Products, 2006-2013
• Table 6.4: Forecasts for Erythropoietin Products, 2018 and 2023
• Table 6.5: Forecasts for Iron Replacement Therapy, 2006-2013
• Table 6.6: Forecasts for Iron Replacement Therapy, 2018 and 2023
• Table 7.1: Forecasts for Clotting Factors, 2006-2013
• Table 7.2: Forecasts for Clotting Factors, 2018 and 2023
• Table 8.1: A SWOT Chart for the Blood Diseases Treatments Market, 2006-2013
• Table 9.1: Revenue and Market Share of the Leading Pharmaceutical Markets, 2006 and 2013
• Table 10.1: Platelet Aggregation Inhibitors in Development, 2008
• Table 10.2: Injectable Anticoagulants in Development, 2008
• Table 10.3: Other Antithrombotics in Development, 2008
• Table 10.4: Erythropoietin Products in Development, 2008
• Table 10.5: Other Anti-anaemics in Development, 2008
• Table 10.6: Clotting Factors in Development, 2008
• Table 10.7: Other Blood Diseases Treatments in Development, 2008
• Table 11.1: Forecasts for Blood Diseases Treatments, 2006-2013

List of Figures

• Figure 4.1: Forecasts for Blood Diseases Treatments by Market Segment, 2006-2013
• Figure 4.2: Blood Diseases Treatments World Market Forecast, 2006-2013
• Figure 4.3: Blood Diseases Treatments Market Share, 2006
• Figure 4.4: Blood Diseases Treatments Market Share, 2013
• Figure 4.5: Changes in Market Share of the Market Segments
• Figure 4.6: Market Share of the Main Drugs, 2006
• Figure 4.7: Market Share of the Main Drugs, 2013
• Figure 4.8: Changes in revenue from 2006 to 2013 by Market Segment
• Figure 5.1: Antithrombotics Market Forecast, 2006-2013
• Figure 5.2: Antithrombotics Market Share, 2006
• Figure 5.3: Antithrombotics Market Share, 2013
• Figure 5.4: Market Share of the Main Antithrombotics, 2006
• Figure 5.5: Market Share of the Main Antithrombotics, 2013
• Figure 5.6: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
• Figure 5.7: Platelet Aggregation Inhibitors Market Forecast, 2006-2013
• Figure 5.8: Market Share of Platelet Aggregation Inhibitors, 2006
• Figure 5.9: Market Share of Platelet Aggregation Inhibitors, 2013
• Figure 5.10: Plavix Forecast, 2006-2013
• Figure 5.11: Clopidogrel Aptx Forecast, 2006-2013
• Figure 5.12: Pletaal Forecast, 2006-2013
• Figure 5.13: Integrilin Forecast, 2006-2013
• Figure 5.14: Forecasts for Injectable Anticoagulants, 2006-2013
• Figure 5.15: Injectable Anticoagulants Market Forecast, 2006-2013
• Figure 5.16: Injectable Anticoagulants Market Share, 2006
• Figure 5.17: Injectable Anticoagulants Market Share, 2013
• Figure 5.18: Lovenox Forecast, 2006-2013
• Figure 5.19: Fraxiparine Forecast, 2006-2013
• Figure 5.20: Fragmin Forecast, 2006-2013
• Figure 6.1: Anti-anaemics Market Forecast, 2006-2013
• Figure 6.2: Anti-anaemics Market Share, 2006-2013
• Figure 6.3: Anti-anaemics Market Share, 2006-2013
• Figure 6.4: Market Share of the Main Anti-anaemics, 2006
• Figure 6.5: Market Share of the Main Anti-anaemics, 2013
• Figure 6.6: Forecasts for Erythropoietin Products, 2006-2013
• Figure 6.7: Erythropoietin Products Market Forecast, 2006-2013
• Figure 6.8: Erythropoietin Products Market Share, 2006
• Figure 6.9: Erythropoietin Products Market Share, 2013
• Figure 6.10: Aranesp Forecast, 2006-2013
• Figure 6.11: Erypo Forecast, 2006-2013
• Figure 6.12: Epogen Forecast, 2006-2013
• Figure 6.13: NeoRecormon Forecast, 2006-2013
• Figure 6.14: Espo Forecast, 2006-2013
• Figure 6.15: Forecasts for Iron Replacement Therapy, 2006-2013
• Figure 6.16: Iron Replacement Therapy Market Forecast, 2006-2013
• Figure 6.17: Iron Replacement Therapy, 2006
• Figure 6.18: Iron Replacement Therapy Market Share 2013
• Figure 6.19: Venofer Forecast, 2006-2013
• Figure 7.1: Forecasts for Clotting Factors, 2006-2013
• Figure 7.2: Clotting Factors Market Forecast, 2006-2013
• Figure 7.3: Clotting Factors Market Share, 2006
• Figure 7.4: Clotting Factors Market Share, 2013
• Figure 7.5: NovoSeven Forecast, 2006-2013
• Figure 9.1: Revenue of the Leading Pharmaceutical Markets, 2006 and 2013
• Figure 9.2: Market Share of the Leading Pharmaceutical Markets, 2006 and 2013
• Figure 11.1: Blood Diseases Treatments World Market Forecast, 2006-2013
• Figure 11.2: Market Share of the Main Drugs, 2006
• Figure 11.3: Market Share of the Main Drugs, 2013
• Figure 11.4: Changes in revenue from 2006 to 2013 by Market Segment
• Figure 11.5: Forecasts for Blood Diseases Treatments by Market Segment, 2006-2013
• Figure 11.6: Market Share of the Leading Pharmaceutical Markets, 2006 and 2013

Organisations Mentioned in this Report

• Advancell
• Affymax
• Akzo Nobel
• AMAG
• Amgen
• Apotex
• Artisan
• Asahi Kasei
• AstraZeneca
• Barcelona University
• Barr
• Baxter International
• Bayer
• Berlex
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Cogentus
• Daiichi Sankyo
• Eli Lilly
• Emisphere
• Flamel Technologies
• Fuso
• GlaxoSmithKline
• Green Cross Corporation
• Hexal
• Hospira
• Human Genome Sciences
• JCR Pharmaceuticals
• Johnson & Johnson
• Kissei
• Ligand
• Lundbeck
• Medicines Company
• MedImmune
• Menarini
• National Cancer Institute
• National Institutes of Health
• Nektar
• Novartis
• Novo Nordisk
• Nuvelo
• Ono
• Ormont
• Ortho-McNeil
• Otsuka
• Ovation Pharmaceuticals
• PAION
• PeriCor
• Pfizer
• Protherics
• RHEI
• Roche
• sanofi-aventis
• Schering-Plough
• Servier
• Snow Brand Milk Products
• Stada
• Takeda
• Taro
• Torii
• Ube
• Watson
• Wyeth